Overview

Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Salmeterol Xinafoate